125.59 0.00 (0.00%)
After hours: 4:55PM EST
|Bid||125.59 x 100|
|Ask||129.95 x 100|
|Day's Range||123.90 - 131.99|
|52 Week Range||35.98 - 147.63|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
CNBC's Meg Tirrell speaks with John Maraganore, Alnylam CEO, about pricing for his company's new drug and his thoughts on Amazon's potential break into the biopharma industry.
Alnylam edged up Friday after the FDA lifted its clinical hold on trials of a hemophilia drug, allowing Alnylam to start administering the drug before year-end.
Three months after Alnylam Pharmaceuticals halted trials of a hemophilia drug due to a patient's death, the Cambridge biotech has gotten permission from the FDA to resume studies. Alnylam (ALNY), one of the state’s largest and most valuable biotechs, stopped the Phase 2 and Phase 3 studies of fitusiran in September after one patient died of brain swelling triggered by a blood clot. The news sank shares of Alnylam, shaving $1 billion from its market cap.
Companies with shares expected to trade actively in Friday's session include CSX, Hess, Adobe Systems, Costco and Aclaris Therapeutics.
Alnylam Pharmaceuticals Inc. shares rose 5% in pre-market trade Friday after the company said the Food and Drug Administration has lifted a hold on clinical trials for hemophilia therapy fitusiran. Alnylam ...
The U.S. Food and Drug Administration has allowed Alnylam Pharmaceuticals Inc to restart clinical trials on a drug to treat patients with a rare bleeding disorder, the company said on Friday. All ongoing studies of the drug, fitusiran, had been placed on clinical hold after Alnylam suspended dosing following a patient death in one of the trials testing the drug in hemophilia patients. Alnylam said the FDA approved amended protocols related to the trials, and it expected to resume dosing patients around the end of the year.
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Alnylam Pharmaceuticals, Inc. a score of 21. Our analysis is based on comparing Alnylam Pharmaceuticals, Inc. with the following peers – Ionis Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc., Medicines Company, Sarepta Therapeutics, Inc., OPKO Health, Inc., Teva Pharmaceutical Industries Limited Sponsored ADR, Sanofi Sponsored ADR, ... Read more (Read more...)
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Alnylam Pharmaceuticals, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish ... Read more (Read more...)
In November 2017, the U.S. Food and Drug Administration (or FDA) granted United Therapeutics’ (UTHR) Adcirca Pediatric exclusivity until May 21, 2018.
Before the approval of Alnylam's first drug, CEO John Maraganore backed the idea of raising prices pegged to inflation.
Chief Executive John Maraganore makes a pledge: “We will not arbitrarily increase prices beyond the price of inflation. We think the most difficult practice to explain to payors and patients is drug price increases. And we will not do that.”
CEO of Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) John Maraganore sold 73,415 shares of ALNY on 11/22/2017 at an average price of $130.9 a share.
Alnylam (ALNY) announced that the FDA has granted Breakthrough Therapy Designation for RNAi therapeutic candidate, patisiran.
Alnylam (ALNY) expects to achieve the profile of three marketed products by the end of 2020 and remains focused on development of its pipeline candidates.
Alnylam's (ALNY) RNAi candidate, patisiran, has been granted accelerated assessment by the European Medicines Agency. The company expects to file new drug application by end of 2017.
The time is drawing near: our sixth annual Forbes Healthcare Summit will be held on Nov. 29 and Nov. 30. The event will take attendees through the whole spectrum of the healthcare business, from the cutting edge of gene therapy and to the hard economic choices every health system must make.